| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2141844 | Lung Cancer | 2010 | 7 Pages |
Abstract
In unselected NSCLC patients with PS 2-3, gefitinib, gemcitabine and docetaxel achieved similar results. Docetaxel was associated with higher rates of adverse events.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Jean-François Morère, Jeanne-Marie Bréchot, Virginie Westeel, Valerie Gounant, Bernard Lebeau, Fabien Vaylet, Fabrice Barlési, Thierry Urban, Pierre-Jean Souquet, Didier Debieuvre, Laurence Baudrin, Gérard Zalcman, Franck Morin, Bernard Milleron,